Abbott Catches Up to Peers With MRI-Compatible ICD
Abbott Laboratories acquired St. Jude Medical earlier this year knowing that the company trailed behind its peers in the cardiac rhythm management (CRM) space by not having a MRI-compatible pacemaker or implantable cardioverter defibrillator (ICD) system. It seems Abbott has officially caught up in that category though, first with FDA approval of the Assurity MRI pacemaker and the Tendril MRI pacing lead during the first quarter, and now with FDA approval of MRI-conditional labeling for the Ellipse ICD system. Abbott said the recent approval covers one of its most widely-used ICD systems and associated high voltage leads. ...
Source: MDDI - September 23, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: MD & M Minneapolis Labeling Business Source Type: news
Abbott wins MR-conditional label for Ellipse ICDs
Abbott (NYSE:ABT) said today that it won an MR-conditional label from the FDA for the Ellipse implantable cardioverter defibrillator it acquired along with St. Jude Medical early this year. The MR-conditional label applies to Ellipse and the Tendril MRI pacing lead and the Durata and Optisure high-voltage leads, the Chicago-area medical device giant said. “When you consider the number of patients each year who rely on the lifesaving treatment delivered by an ICD device, it is critical to continually innovate to provide new benefits to people battling complex arrhythmias and other cardiac conditions,” cardiac ar...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Food & Drug Administration (FDA) Imaging Regulatory/Compliance Abbott Cardiac Rhythm Management Source Type: news
Is BioSig for Real This Time With Its Pure EP?
A couple years ago, BioSig Technologies, Inc. was poised to apply for FDA clearance to market its technology to improve treatment of atrial fibrillation and ventricular tachycardia. Then its scientific advisors advised the Minneapolis company to put more work into that technology, a hardware-software combination designed to present clearer signals during electrophysiology studies and catheter ablation. The technology, Pure EP, is designed to cut through the background noise of the lab and its equipment during cardiac recordings, enabling physicians to target and neutralize the areas of the heart that are causing atria...
Source: MDDI - September 7, 2017 Category: Medical Devices Authors: Nancy Crotti Tags: MD & M Minneapolis R Software Source Type: news
Abbott wins FDA nod for HeartMate 3 pump
Abbott (NYSE:ABT) said today that the FDA approved its HeartMate 3 implantable pump for heart failure patients awaiting a transplant. The approval is the latest for the HeartMate line of left ventricular assist devices first developed by Thoratec, which was later acquired by St. Jude Medical before a $25 billion merger brought it to Abbott earlier this year. Abbott said HeartMate 3 features full magnetic levitation for the pump’s impeller, aiming to cause less trauma to blood cells as they pass through the pump. Although it is smaller than its predecessor, Abbott claimed it has the industry’s largest ...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Food & Drug Administration (FDA) Abbott Source Type: news
Numerate receives NIH funding to discover new anti-arrhythmic treatments
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded a small business innovation research (SBIR) Phase I grant to Numerate to boost a new drug programme for cardiac arrhythmias. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news
Not all astrocytes in the brain are the same, study finds
From afar, the billions of stars in our galaxy look indistinguishable, just as the billions of star-shaped astrocytes in our brains appear the same as each other. But UCLA researchers have now revealed that astrocytes, a type of brain cell that supports and protects neurons, aren ’t all the same. While stars might be categorized by their size, age and heat, the supportive brain cells vary when it comes to shape, molecular machinery and functioning.The findings,published today in the journal Neuron, should make it easier for researchers to study how astrocytes relate to disease, or to develop drugs that aim...
Source: UCLA Newsroom: Health Sciences - July 13, 2017 Category: Universities & Medical Training Source Type: news
CathVision inks investment deal for electrophysiology system
Early-stage medical device company CathVision said today it inked a “multi-million venture investment” to support the development and marketing of its electrophysiology recording system designed for treating cardiac arrhythmia. The undisclosed investment came from Scandanavian-based VF Venture and Borean Innovation, Denmark-based CathVision said. “CathVision works in one of the fastest growing segments in medical technology. CathVision’s team has worked patiently and consistently with their product over a number of years, and we have followed the company for several years. I think CathVision represe...
Source: Mass Device - July 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular cathvision Source Type: news
Adverse Drug Event Causality Analysis (ADECA): a process for evaluating evidence and assigning drugs to risk categories for sudden death - Woosley RL, Romero K, Heise CW, Gallo T, Tate J, Woosley RD, Ward S.
Growing evidence indicates that many drugs have the ability to cause a potentially lethal cardiac arrhythmia, torsades de pointes (TdP). This necessitates the development of a compilation of drugs that have this potential toxicity. Such a list is helpful i... (Source: SafetyLit)
Source: SafetyLit - June 24, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Tenth year of data on cardiac arrhythmia treatment launched at European congress
(European Society of Cardiology) The tenth year of data on cardiac arrhythmia treatment is being launched at EHRA EUROPACE - CARDIOSTIM 2017. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 18, 2017 Category: International Medicine & Public Health Source Type: news
Medical News Today: Does the sound of airplanes raise blood pressure risk?
A new study investigates the effect of long-term exposure to aircraft noise on the risk of high blood pressure, cardiac arrhythmia, and stroke. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2017 Category: Consumer Health News Tags: Public Health Source Type: news
Lessons from Fire Prevention: Why We Can Head Off Disease Without Sacrificing Cure
This insightful and data-filled evidence-based article from the Boston University School of Public Health illustrates the work EMS can, and should, do to prevent disease where we cannot control curing it: Public health is concerned with creating a healthier world, preferably one where we prevent disease before it starts. This inevitably occasions grappling with our overwhelming investment in medicine and curative care, and arguing for a recalibration of our investment towards the social, economic, and cultural factors that promote health. We can educate people how to reduce their chances of suffering heart attacks, ...
Source: JEMS: Journal of Emergency Medical Services News - June 11, 2017 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT P Tags: Training News Source Type: news
Acute alcohol intoxication in an eight weeks old infant - Frenkel Rutenberg T, Benacun M.
INTRODUCTION: Alcohol intoxication in infants is a life-threatening condition which requires early diagnosis and treatment. It may lead to multi-system injury, including mental deterioration, respiratory depression, cardiac arrhythmia, metabolic disorders ... (Source: SafetyLit)
Source: SafetyLit - June 1, 2017 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Bathroom scales will inform about life threatening conditions
(Kaunas University of Technology) Weighing oneself has become one of the most common morning rituals. However, your weight is not the only message that can be delivered by your bathroom scales: the team of researchers at Kaunas University of Technology (KTU) Institute of Biomedical Engineering are developing the multifunctional scales, which can monitor your health and inform about potentially dangerous life conditions, such as arteriosclerosis or cardiac arrhythmia. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 16, 2017 Category: Biology Source Type: news
Arthur Moss Receives Heart Rhythm Society ’s Pioneer in Cardiac Pacing and EP Award
Arthur J. Moss, M.D., received the award for his dedication to understanding and treating electrical disturbances of the heart, including cardiac arrhythmias, sudden cardiac death, heart failure and Long QT syndrome. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - May 12, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Abbott wins CE Mark for new TactiCath ablation catheter
Abbott (NYSE:ABT) said today that the TactiCath sensor-enabled ablation catheter it bought along with St. Jude Medical (NYSE:STJ) this year won CE Mark approval in the European Union. The Chicago-area healthcare giant said the new TactiCath device can be integrated with another St. Jude product, the EnSite Precision heart mapping system it launched earlier this year. “The goal in developing the TactiCath contact force ablation catheter, sensor enabled, was to provide the most innovative solution for treating atrial fibrillation and lead the way in clinical outcomes for patients with cardiac arrhythmias &nda...
Source: Mass Device - May 9, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Catheters Regulatory/Compliance Wall Street Beat Abbott stjudemedical Source Type: news
Abbott wins CE Mark for Confirm Rx cardiac monitor
Abbott (NYSE:ABT) said today that its St. Jude Medical (NYSE:STJ) subsidiary won CE Mark approval in the European Union for the ConfirmRx insertable cardiac monitor, touting as the world’s 1st smartphone-compatible ICM. The continuous heart monitor is designed to work with St. Jude’s myMerlin mobile app to allow physicians to remotely follow patients and diagnose arrhythmias. Abbott said it’s on the market in 10 “select” countries in Europe, with a full release slated for the 2nd quarter. The FDA is also reviewing the device, the Chicago-area healthcare giant said. &l...
Source: Mass Device - May 8, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Patient Monitoring Regulatory/Compliance Abbott st-jude-medical Source Type: news
Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor
Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe. (Source: eHealth News EU)
Source: eHealth News EU - May 8, 2017 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news
Abbott announces CE Mark and first use of the world's first smartphone compatible insertable cardiac monitor
Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe. (Source: World Pharma News)
Source: World Pharma News - May 8, 2017 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news
Digital health news briefs for 5/4/2017: CardioNet HIPAA settlement, Telemedicine lactation consulting
OCR settles HIPAA complaint with CardioNet. CardioNet, one of the oldest companies in the mobile cardiac arrhythmia monitoring space, has agreed to pay the Office of Civil Rights $2.5 million and enter into a corrective action plan in the end result of a HIPAA breach investigation that's been going on since 2012. (Source: mobihealthnews)
Source: mobihealthnews - May 4, 2017 Category: Information Technology Source Type: news
Advanced Cardiac Therapies lands $45m round led by new PE shop Ajax Health
Ajax Health, the medical device portfolio management company newly formed by KKR and Aisling Capital, led a $45 million round for Advanced Cardiac Therapeutics and the next-generation ablation catheter it’s developing. Earlier today the private equity giants launched tapped Spirox chairman & CEO Duke Rohlen to lead Ajax Health. Rohlen, the former president of FoxHollow Technologies and the founder & former chief executive of CV Ingenuity, is also CEO at ACT. That Santa Clara, Calif.-based company said existing backer New Enterprise Assoc. and new inv...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Catheters Funding Roundup Wall Street Beat Advanced Catheter Therapies ajaxhealth New Enterprise Associates questa Source Type: news
Binge drinking could trigger abnormal heart rhythms
Conclusion This cross-sectional study found binge drinking is associated with an increased risk of having an irregular heartbeat. However, the type of irregular heartbeat found was mainly sinus tachycardia, which isn't life threatening but involves the heart beating at an abnormally fast rate of over 100 heartbeats a minute. This research also has some notable limitations: The ECG recordings from the acute alcohol group were taken using a smartphone application operated outside the manufacturer's recommended environment. The lively atmosphere within the beer tent may have caused inaccurate recordings. The population...
Source: NHS News Feed - April 27, 2017 Category: Consumer Health News Tags: Heart/lungs Lifestyle/exercise Source Type: news
AliveCor raises $30m
AliveCor has raised $30.1 million in a new round of equity financing, according to an SEC filing posted this week. The Mountain View, Calif.-based company produces the Kardia mobile platform, which includes smartphone apps and accessories to allow for the monitoring of multiple vital signals. AliveCor’s monitoring app can record 5 vital statistics, the company said, including blood pressure, heart rhythm, resting heart rate, weight and physical activity. Money in the round comes from 9 unnamed investors, with the 1st sale in the round dated on March 15, according to the SEC filing. The company has not yet said how it...
Source: Mass Device - March 31, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Diagnostics mHealth (Mobile Health) AliveCor Source Type: news
Heart Societies update guidelines to support cardiac monitors for syncope patients
Medtronic (NYSE:MDT) said today that new guidelines from the American College of Cardiology, the American Heart Association and the Heart Rhythm Society now recommend the use of cardiac monitors for patients with syncope. The updated guidelines for patients with syncope, or unexplained fainting, was published online in the Journal of the American College of Cardiology, Circulation and HeartRhythm. Medtronic said that the new guidelines support the use of its Seeq MCT system, a wireless continuous external heart monitor that can be worn up to 30 days, and its Reveal Linq ICM with TruRhythm detection, an implantabl...
Source: Mass Device - March 24, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Patient Monitoring Medtronic Source Type: news
AliveCor raises $30m, launches Kardia Pro platform in U.S.
AliveCor said today that it landed $30 million in a series D funding round and that it released its artificial intelligence-enabled Kardia Pro platform in the U.S. The company’s platform enables doctors to remotely monitor their patients for early signs of atrial fibrillation, a common cardiac arrhythmia. “Heart disease is the No. 1 cause of death in the United States, claiming more lives than all forms of cancer combined. To manage heart disease and stroke risk, leading cardiologists want to see more than just ECGs from their patients,” CEO Vic Gundotra said in prepared remarks. “Kardia P...
Source: Mass Device - March 16, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Cardiovascular Funding Roundup Patient Monitoring Wall Street Beat AliveCor Source Type: news
Abbott announces FDA approval of Flexibility < sup > TM < /sup > Ablation Catheter, Sensor Enabled < sup > TM < /sup > to advance the treatment of complex cardiac arrhythmias
- Sensor EnabledTM tool complements the EnSite PrecisionTM cardiac mapping system and expands Abbott's comprehensive advanced cardiac mapping and ablation portfolio (Source: Abbott.com)
Source: Abbott.com - March 1, 2017 Category: Pharmaceuticals Source Type: news
Abbott wins FDA nod for FlexAbility sensor-enabled ablation cath
Abbott (NYSE:ABT) said today it won FDA approval for its sensor-enabled FlexAbility ablation catheter designed for cardiac ablation procedures to treat atrial flutter. The sensor-enabled FlexAbility ablation catheter is the Abbott Park, Ill.-based company’s 1st designed to collect electrical current resistance and magnetic data to produce accurate mapping and assist in treating sites that trigger or sustain abnormal heart rhythms. “I am seeing an increasing number of patients with complex cardiac arrhythmias, which has created a strong need for advanced tools that can meet the needs of those patients. Sensor En...
Source: Mass Device - March 1, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news
Must-watch: video showing murder of Kim Jong Nam
Discussion on toxicology discussion boards have brought up the following possibilities: Tetramine: Tetramethylenedisulfotetramine (TETS) is a rat poison that has been banned since 1984 but which — according to Wikipedia — is still used in China. It is a white powder that is slightly soluble both in water and DMSO, a solvent that could accelerate dermal absorption. TETS is a neurotoxin that acts as a GABA antagonist causing refractory status epileptics, coma, and death. There is no specific antidote. Aconite: This plant poison is used in several Chinese herbal medicines.Aconite is a sodium channel opener, ...
Source: The Poison Review - February 22, 2017 Category: Toxicology Authors: Leon Gussow Tags: Medical assassination Kim Jong Nam Kuala Lumpur International Airport malaysia murder North Korea Source Type: news
Medtronic wins FDA clearance for CardioInsight 3D mapping tech
Medtronic (NYSE:MDT) said today that it won 510(k) clearance from the FDA for its CardioInsight Noninvasive 3D mapping system, which was designed to map irregular heart rhythms in the upper and lower chambers of the heart and provide electroanatomic 3D maps of the heart. The CardioInsight system is the 1st commercially available, noninvasive cardiac electrical mapping system in the world, according to Medtronic, and avoids the invasive steps of a traditional procedure to determine the origin of a patient’s irregular heart rhythm. Medtronic’s 3D cardiac mapping system employs a 252-electrode sensor vest, which i...
Source: Mass Device - February 1, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: 510(k) Cardiovascular Food & Drug Administration (FDA) Regulatory/Clearance Medtronic Source Type: news
Atrial fibrillation more prevalent in dialysis patients than expected
Atrial fibrillation, which is the most common cardiac arrhythmia, is an important risk factor for strokes. A multi-centre study shows that the prevalence of atrial fibrillation in haemodialysis patients in Vienna is significantly higher than previously thought. Moreover, only half of the patients affected are treated with an anticoagulant. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 16, 2017 Category: Science Source Type: news
Hypothermia Diagnosis and Treatment Could Save Lives
Hypothermia is a life threatening condition that may result in death. It is a drop in the core body temperature of less than 95°F (35° Celsius). This temperature is below what is required for normal metabolism and bodily function (Figure 1). The normal body temperature is between 97.7°F and 99.5°F (Fahrenheit) which is the same as 36.5°C and 37.5°C (Celsius). The body's thermoregulation mechanism adjusts to weather changes. Thermoregulation During extreme cold, the body receives a signal from sensory receptors. The signal will go up to the brain. The brain then sends a signal to the body to resp...
Source: Healthy Living - The Huffington Post - January 13, 2017 Category: Consumer Health News Source Type: news
Warmer Oceans Increase Likelihood Of Toxic Shellfish, Study Finds
The neurotoxin domoic acid inspired Alfred Hitchcock’s “The Birds” after hundreds of sooty shearwaters ingested the poison in the summer of 1961 and, well, lost their minds. The crazed birds likely consumed domoic acid via small fish like anchovies and sardines. It also tends to collect in shellfish, like clams, crabs and lobsters. And, according to a study published Tuesday in the Proceedings of the National Academy of Sciences, it may become more prevalent as oceans warm, threatening birds and humans alike. Researchers at Oregon State University, the University of Oregon, the National Oce...
Source: Science - The Huffington Post - January 11, 2017 Category: Science Source Type: news
Biotronik launches BioMonitor 2 subcutaneous heart monitor trial
Biotronik said today it enrolled the 1st patients in the BioInsight clinical study of its BioMonitor 2 heart monitor, which looks to investigate the feasibility implanting the BioMonitor 2 in office settings. The BioMonitor 2 device is designed for remote monitoring of patients with atrial fibrillation, syncope, bradycardia and tachychardia, Biotronik said. The device uses Biotronik’s ProMRI technology and is approved for full-body MRI scans at 1.5 and 3 tesla strength. “One of the benefits of BioMonitor 2 is the ease of the insertion procedure, which typically only takes a few minutes. In-office proc...
Source: Mass Device - December 5, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Clinical Trials Patient Monitoring Biotronik Source Type: news
Macrophage-dependent IL-1 & #946; production induces cardiac arrhythmias in diabetic mice
(D'Or Institute for Research and Education) One of the most serious complications of diabetes, heart arrhythmias, is now on its way to be prevented and combated. Heart problems are responsible for 65 percent of the deaths related to diabetes. This work confirms that the increase in blood glucose causes a specific inflammation, which directly affects the heart. Here the authors propose new therapeutic tools that are promising to treat the heart disease caused by diabetes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 24, 2016 Category: Global & Universal Source Type: news
UPDATE: Apama Medical raises $20m
Updated to include new information from Apama Medical Novel catheter ablation tech developer Apama Medical said it raised a total of $19.7 million, with $13.2 million coming from a closed Series C round and $6.5 million from a debt facility with Silicon Valley Bank. Apama Medical is developing novel ablation catheter technology to combine “the best elements of existing ablation technology while incorporating additional unique features to address gaps in current technology,” according to it’s website. The Series C round was joined by Ascension Ventures, Medvance Incubator Partners, ONSE...
Source: Mass Device - November 18, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Catheters Funding Roundup Wall Street Beat Apama Medical Source Type: news
Genetesis lands $1m seed round for CardioFlux heart imaging device
Genetesis said today that it raised a $1.2 million seed round for its CardioFlux heart imaging device. Cincinatti-based Genetesis said the round was led by CincyTech and Mark Cuban’s Radical Investments and included Loud Capital, Danmar Capital, Wilson Sonsini Investment Company, Genetesis management and private angels. The CardioFlux device is designed to create a 3D map to characterize the heart’s underlying electrical activity in patients with myocardial ischemia, atrial fibrillation, ventricular tachycardia and other cardiac arrhythmias. The company said it plans to use the pro...
Source: Mass Device - November 14, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Funding Roundup Imaging Genetesis Source Type: news
Japan approves St. Jude Medical ’ s EnSite, TactiCath
St. Jude Medical (NYSE:STJ) said today it won Japanese MHLW approval for its EnSite Precision cardiac mapping system and its TactiCath irrigated ablation catheter. The Ensite cardiac mapping system is designed for use in ablation procedures to visualize and aid in catheter navigation in the heart, providing detailed anatomical models and maps, St. Jude said. The system is designed to aid in diagnosing arrhythmias, guiding therapy and providing expanded procedural options. The St. Paul, Minn.-based company’s TactiCath quartz irrigated ablation catheter is designed for ablation procedures to treat atrial fibr...
Source: Mass Device - November 2, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Imaging Regulatory/Compliance St. Jude Medical Source Type: news
St. Jude launches EnSite Precision cardiac mapping system in EU
St. Jude Medical (NYSE:STJ) said today it fully launched its EnSite Precision cardiac mapping system and associated tools in Europe, expanding from an earlier limited release. The St. Paul, Minn.-based company touted more than 100 installations of the device across Europe so far, supporting more than 5,000 ablation procedures after a targeted release it expanded in April. “We collaborated with leading electrophysiologists to develop a cardiac mapping system that provides the automation, flexibility and precision needed during today’s ablation procedures. We are extremely pleased with how the physicians fro...
Source: Mass Device - October 5, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Imaging Regulatory/Compliance St. Jude Medical Source Type: news
Complex Fetal Care: Importance of Fetal Arrhythmias to the Neonatologist and Pediatrician
Sudden unexplained death during the perinatal period remains a major longstanding challenge. Recent advances in diagnostic techniques and genetic testing have provided evidence that a significant fraction of these deaths may result from lethal cardiac arrhythmias. In this article, we review current methods of diagnosing arrhythmia in the fetus and strategies for managing life-threatening arrhythmia throughout the perinatal period, including transitional care at the time of delivery. (Source: NeoReviews recent issues)
Source: NeoReviews recent issues - September 29, 2016 Category: Pediatrics Authors: Wacker-Gussmann, A., Wakai, R. T., Strasburger, J. F. Tags: Pediatric Drug Labeling Update Articles Source Type: news
Medtronic touts CRT study showing heightened medication adherence
Patients implanted with cardiac resynchronization devices showed a greater rate of adherence to their medication regiments after their CRT devices were put it, according to a retrospective study Medtronic (NYSE:MDT) touted today. The analysis examined data from 4,512 patients who received CRT devices between January 2008 and December 2014, evaluating adherence to recommended medications before and after CRT implantation. Compliance increased 67% 2 years after CRT implantation when compared to 2 years pre-implantation, Fridley, Minn.-based Medtronic said. “These data support our commitment to understanding how we...
Source: Mass Device - September 19, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Clinical Trials Cardiac Rhythm Management Medtronic Source Type: news
MassDevice.com +5 | The top 5 medtech stories for September 14, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. Light-based arrhythmia treatment skips the shocks Researchers at Johns Hopkins University and Germany’s University of Bonn showed that light can restore a normal heartbeat and replace electric shocks in patients at risk f...
Source: Mass Device - September 14, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Light-based arrhythmia treatment skips the shocks
Researchers at Johns Hopkins University and Germany’s University of Bonn showed that light can restore a normal heartbeat and replace electric shocks in patients at risk for arrhythmia, according to a press release from the Baltimore school. The work was published online yesterday in the Journal of Clinical Investigations and could 1 day be used to develop implantable defibrillators, the team suggested. A standard defibrillator uses electrical shocks to jump-start the heart when a patient experiences arrhythmia, a potentially deadly irregular heartbeat. The shocks can be painful and damage the heart tissue. Researche...
Source: Mass Device - September 14, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Cardiovascular Research & Development Cardiac Rhythm Management Johns Hopkins University of Bonn Source Type: news
Japan approves Medtronic ’ s Reveal Linq cardiac monitor
Medtronic (NYSE:MDT) wasted no time in launching its Reveal Linq cardiac monitor in Japan, saying it plans to launch the device there this month now that the device won approval from the Ministry of Health, Labor & Welfare. The Reveal Linq device is designed to be implanted beneath the skin on the upper left side of the chest for monitoring patients experiencing dizziness, palpitation, fainting or syncope, chest pain and cardiac arrhythmias. Billed as the world’s smallest cardiac monitor, it’s about ⅓ the size of a triple-A battery and is designed to work for 3 years using the company’s CareLin...
Source: Mass Device - September 14, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Patient Monitoring Regulatory/Compliance Medtronic Source Type: news
What Causes Hyperphosphatemia?
Discussion Constipation is a common problem in general pediatrics and its causes are numerous. It can cause acute and recurrent abdominal pain and is a cause of abdominal distention. Patients who are young, whose presentations are other than routine or who had complications should be invested for underlying causes of their constipation. This patient had undergone some evaluations in the past for constipation but because of the presentation of sepsis a more rigorous evaluation was undertaken. The differential diagnoses of the following can be found here: constipation, acute abdominal pain, recurrent abdominal pain, and abdo...
Source: PediatricEducation.org - September 12, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
[In Depth] A painstaking overhaul for cardiac safety testing
It's a crucial step in drug development: testing a compound to gauge whether it might cause cardiac arrhythmia. For years, researchers and drug developers have worried that standard preclinical tests for cardiac safety are actually too conservative, and may lead drugmakers to abandon promising and safe treatments early in development. Since 2013, an international team of regulators, academic researchers, and drug companies have been validating a more sophisticated set of tests, known as the Comprehensive in vitro Proarrhythmia Assay (CiPA). That painstaking process is inching toward completion. In the coming weeks, a key c...
Source: ScienceNOW - September 1, 2016 Category: Science Authors: Kelly Servick Tags: Drug Development Source Type: news
[This Week in Science] Genetic underpinnings of atrial fibrillation
Author: Katrina L. Kelner (Source: ScienceNOW)
Source: ScienceNOW - September 1, 2016 Category: Science Authors: Katrina L. Kelner Tags: Cardiac Arrhythmia Source Type: news
Influence of ambient temperature and diurnal temperature range on incidence of cardiac arrhythmias - Kim J, Kim H.
We investigated the association between ambient temperature and diurnal temperature range (DTR) and the exacerbation of arrhythmia symptoms, using data from 31,629 arrhythmia-related emergency department (ED) visits in Seoul, Korea. Linear regression analy... (Source: SafetyLit)
Source: SafetyLit - August 31, 2016 Category: Global & Universal Tags: Environmental Issues, Climate, Geophysics Source Type: news
CyberHeart inks development deal with Japan ’ s National Cancer Center
Cardiovascular radiosurgery developer CyberHeart said today it inked its 1st development deal to install its CyberHeart system in Tokyo’s National Cancer Center, making it the 1st non-invasive cardiac radiosurgery treatment in Asia. The CyberHeart system is a non-invasive robotic assisted ablation treatment that uses image-guided tracking of intra-cardiac and other ablation targets for personalized treatments based on a patient’s anatomy, the Mountain View, Calif.-based company said. “We are excited to offer our patients the most advanced, painless and non-invasive treatment for cardiovascular conditions,...
Source: Mass Device - August 8, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Robot-Assisted Surgery Robotics CyberHeart Source Type: news
Mother's plea to test teens for cardiac arrhythmia after losing daughter to condition
John and Heather Reid, of Nottingham, have called for blanket heart testing for 12-to-39-year-olds after they lost their 16-year-old daughter Alexandra to an undiagnosed cardiac condition. (Source: the Mail online | Health)
Source: the Mail online | Health - August 8, 2016 Category: Consumer Health News Source Type: news
Medical device maker VytronUS raises $49M to treat heart problems
Medical device startup VytronUS raised $49 million in funding on Friday to help validate its imaging platform for the treatment of cardiac arrhythmias. Apple Tree Partners, New Enterprise Associates, BioStar Ventures and Windham Venture Partners participated in the Series C round. The Sunnyvale company has raised $101 million to date. CEO John Pavlidis heads up the business, which was founded in 2006. The VytronUS system creates a high-resolutio n image of the interior of the heart. "We have developed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 29, 2016 Category: Pharmaceuticals Authors: Gina Hall Source Type: news
VytronUS, Inc. Raises $49 Million in Series C Financing
SUNNYVALE, Calif., July 29, 2016 -- (Healthcare Sales & Marketing Network) -- VytronUS, Inc. ("VytronUS"), a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that it ha... Devices, Cardiology, Venture CapitalVytronUS, Low-Intensity Collimated Ultrasound, LICU, atrial fibrillation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 29, 2016 Category: Pharmaceuticals Source Type: news